Egetis Therapeutics AB (publ)

LSE:0ABW Stock Report

Market Cap: SEK 2.3b

Egetis Therapeutics Management

Management criteria checks 2/4

Egetis Therapeutics' CEO is Nicklas Westerholm, appointed in Jun 2017, has a tenure of 7.58 years. directly owns 0.068% of the company’s shares, worth SEK1.53M. The average tenure of the management team and the board of directors is 7.6 years and 6.6 years respectively.

Key information

Nicklas Westerholm

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7.6yrs
CEO ownership0.07%
Management average tenure7.6yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nicklas Westerholm's remuneration changed compared to Egetis Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 319m

Jun 30 2024n/an/a

-SEK 319m

Mar 31 2024n/an/a

-SEK 327m

Dec 31 2023n/an/a

-SEK 327m

Sep 30 2023n/an/a

-SEK 319m

Jun 30 2023n/an/a

-SEK 286m

Mar 31 2023n/an/a

-SEK 240m

Dec 31 2022SEK 6mSEK 3m

-SEK 194m

Sep 30 2022n/an/a

-SEK 148m

Jun 30 2022n/an/a

-SEK 113m

Mar 31 2022n/an/a

-SEK 114m

Dec 31 2021SEK 5mSEK 3m

-SEK 104m

Sep 30 2021n/an/a

-SEK 147m

Jun 30 2021n/an/a

-SEK 153m

Mar 31 2021n/an/a

-SEK 155m

Dec 31 2020SEK 4mSEK 2m

-SEK 178m

Sep 30 2020n/an/a

-SEK 127m

Jun 30 2020n/an/a

-SEK 134m

Mar 31 2020n/an/a

-SEK 127m

Dec 31 2019SEK 3mSEK 2m

-SEK 61m

Sep 30 2019n/an/a

-SEK 61m

Jun 30 2019n/an/a

-SEK 48m

Mar 31 2019n/an/a

-SEK 46m

Dec 31 2018SEK 3mSEK 2m

-SEK 85m

Compensation vs Market: Insufficient data to establish whether Nicklas's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Nicklas's compensation has increased whilst the company is unprofitable.

CEO

Nicklas Westerholm (48 yo)

7.6yrs

Tenure

SEK 5,900,000

Compensation

Mr. Nicklas Westerholm has been the Chief Executive Officer of Egetis Therapeutics AB (publ) (formerly known as PledPharma AB (publ)) since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca...

Leadership Team

NamePositionTenureCompensationOwnership
Nicklas Westerholm
Chief Executive Officer7.6yrsSEK 5.90m0.068%
SEK 1.5m
Torsten Almén
Founder19yrsno datano data
Ingemar Lundström
Founder19yrsno datano data
Louis Ignarro
Founder19yrsno datano data
Heidi Brurok
Founder19yrsno datano data
Rob Towart
Founder19yrsno datano data
Yilmaz Mahshid
Chief Financial Officer3.6yrsno data0.087%
SEK 2.0m
Katayoun Welin-Berger
Vice President of Operations1.8yrsno datano data
Jacques Näsström
Chief Scientific Officerno dataSEK 655.00kno data
Karl Hard
VP and Head of Investor Relations & Communication2.9yrsno datano data
Laetitia Szaller
General Counsel & Head of Compliance1.1yrsno datano data
Peter Verwaijen
Global Head of Marketing & Brand Strategy2.7yrsno datano data

7.6yrs

Average Tenure

62yo

Average Age

Experienced Management: 0ABW's management team is seasoned and experienced (7.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Dart
Member of Scientific Advisory Board6.6yrsno datano data
Mats Blom
Chairman of the Board3.8yrsSEK 300.00k0.87%
SEK 19.7m
Behshad Sheldon
Independent Director2yrsno datano data
Thomas Lonngren
Director3.8yrsSEK 600.00k0.079%
SEK 1.8m
Gunilla Osswald
Independent Director8yrsSEK 200.00k0.011%
SEK 251.9k
Elisabeth Svanberg
Independent Director8yrsSEK 200.00k0.010%
SEK 237.4k
Laura James
Member of Scientific Advisory Board6.6yrsno datano data
James Dear
Member of Scientific Advisory Boardno datano datano data

6.6yrs

Average Tenure

63yo

Average Age

Experienced Board: 0ABW's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 10:13
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Egetis Therapeutics AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Patrick LangstromABG Sundal Collier Sponsored
Oscar Haffen LammBryan Garnier & Co